Aratana Therapeutics, Inc. Announces Proposed Public Offering

LEAWOOD, Kan., Nov. 27, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats, today announced that it is commencing an underwritten registered public offering of $35,000,000 of shares of its common stock. All of the shares are being offered by Aratana Therapeutics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Aratana also expects to grant to the underwriters a 30-day option to purchase up to an additional $5,250,000 of shares of common stock.  

Aratana Therapeutics logo

Barclays and Credit Suisse are acting as joint book-running managers for the offering. 

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on August 4, 2017, which became effective on August 16, 2017. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A preliminary prospectus supplement describing the terms of the offering will be filed with the Securities and Exchange Commission and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, from Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department,, (888) 603-5847; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Dept., One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037 or by email at

For investor inquires: 
Craig Tooman  
(913) 353-1026

For media inquiries: 
Rachel Reiff  
(913) 353-1050

SOURCE Aratana Therapeutics, Inc.